FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168111521> ?p ?o ?g. }

• W3168111521 endingPage "1615" @default.
• W3168111521 startingPage "1615" @default.
• W3168111521 abstract "1615 Objectives: Nicotinic acetylcholine receptors (nAChRs) α4β2* subtype play an important role in the CNS and have been implicated in neurodegeneration. In Parkinson’s disease (PD), aggregation of misfolded α-synuclein in intracellular inclusions, Lewy bodies (LB) are some hallmarks of human PD. Our preliminary work using [18F]Nifene on postmortem human PD brain slices and other reported work suggests a potential loss of α4β2* nAChRs in PD. To study α-synucleinopathy in vivo, we have now used the transgenic Hualpha-Syn(A53T) PD mouse model which expresses the A53T mutant α-synuclein protein at six times the level of endogenous mouse of α-synuclein. Here we report our preliminary findings on [18F]Nifene PET/CT in the Hualpha-Syn(A53T) PD mouse model. Methods: Male and female hemizygous Hualpha-Syn(A53)T and no-carrier male and female (n=4) 11-month old mice from Jackson Labs were used in the study. All mice were fasted for at least 24 hours. [18F]Fluoride (from PETNET solutions) was used to prepare [18F]Nifene, which was injected intraperitoneally in normal saline (1.2 MBq in 0.1 mL) under 2% isoflurane anesthesia. Mice were then awake after [18F]Nifene injections and free to move in their cages. They were placed in the supine position in a mouse holder and anesthetized with 2% isoflurane for whole-body PET/CT imaging. All mice underwent a 15 minute-long PET scans were acquired 45 minutes after [18F]Nifene injections. All animals had a 7-minute-long CT scan before the PET scan for attenuation correction and anatomical delineation of PET images. An Inveon Multimodality (MM) CT scanner (Siemens Medical Solutions, Knoxville, TN) was used for CT acquisitions in combined PET/CT experiments. Results: The magnitude of [18F]Nifene uptake in the brain was expressed as standard uptake value (SUV) which was computed as the average [18F]Nifene activity in each volume of interest, VOI (in kBq/mL) divided by the injected dose (in MBq) times the bodyweight (Kg) of each animal (Fig-1A-C). [18F]Nifene binding in the no-carrier mouse was as expected, with the highest levels in the thalamus (Fig-1B). Hualpha-Syn(A53) mice had lower [18F]Nifene uptake in the midbrain and cortex compared to the no-carrier mice. SUV values Hualpha-Syn(A53): midbrain=0.57-0.64; cortex=0.54-0.67 versus no-carrier midbrain=1.09-1.45; cortex=1.07-1.39. The hemizygous mice develop adult-onset neurodegenerative disease between 9-16 months of age, with a progressive motoric dysfunction leading to death. [18F]Nifene SUV values in the thalamus were reduced in the Hualpha-Syn(A53) mice, while cortex was not significantly affected (Fig-1A). One Hualpha-Syn(A53) mouse, with no signs of abnormal physical activity or abnormal brain CT or abnormal [18F]FDG PET, exhibited unusually high [18F]Nifene activity in the frontal cortex (Fig-1C). Conclusion: Decreased [18F]Nifene uptake in the Hualpha-Syn(A53) PD mouse model was observed at 11 months of age. Longitudinal [18F]Nifene PET/CT studies are currently underway with more animals (n=12; Hualpha-Syn(A53) and no-carrier) to further validate these initial findings.Figure LegendFigure-1: [18F]Nifene uptake in a Parkinson’s disease alpha-synucleinopathy mouse model. Hualpha-Syn(A53T) mouse brain shows reduced thalamus (TH) [18F]Nifene uptake (A) compared to the no-carrier mouse brain shown in (B). Abnormal uptake of [18F]Nifene in the frontal cortex (FC) in a Hualpha-Syn(A53) female mouse is shown in (C)." @default.
• W3168111521 created "2021-06-22" @default.
• W3168111521 creator A5020767222 @default.
• W3168111521 creator A5028697498 @default.
• W3168111521 creator A5063821904 @default.
• W3168111521 creator A5066786847 @default.
• W3168111521 date "2021-05-01" @default.
• W3168111521 modified "2023-09-22" @default.
• W3168111521 title "[18F]Nifene PET/CT Studies in Parkinson’s Disease A53T Mouse Model of a-Syncleinopathy" @default.
• W3168111521 hasPublicationYear "2021" @default.
• W3168111521 type Work @default.
• W3168111521 sameAs 3168111521 @default.
• W3168111521 citedByCount "0" @default.
• W3168111521 crossrefType "journal-article" @default.
• W3168111521 hasAuthorship W3168111521A5020767222 @default.
• W3168111521 hasAuthorship W3168111521A5028697498 @default.
• W3168111521 hasAuthorship W3168111521A5063821904 @default.
• W3168111521 hasAuthorship W3168111521A5066786847 @default.
• W3168111521 hasConcept C102230213 @default.
• W3168111521 hasConcept C104317684 @default.
• W3168111521 hasConcept C126322002 @default.
• W3168111521 hasConcept C134018914 @default.
• W3168111521 hasConcept C141035611 @default.
• W3168111521 hasConcept C142724271 @default.
• W3168111521 hasConcept C150903083 @default.
• W3168111521 hasConcept C185592680 @default.
• W3168111521 hasConcept C207001950 @default.
• W3168111521 hasConcept C2775842073 @default.
• W3168111521 hasConcept C2776359302 @default.
• W3168111521 hasConcept C2776925932 @default.
• W3168111521 hasConcept C2779134260 @default.
• W3168111521 hasConcept C2989005 @default.
• W3168111521 hasConcept C3017724952 @default.
• W3168111521 hasConcept C42219234 @default.
• W3168111521 hasConcept C55493867 @default.
• W3168111521 hasConcept C71924100 @default.
• W3168111521 hasConcept C86803240 @default.
• W3168111521 hasConceptScore W3168111521C102230213 @default.
• W3168111521 hasConceptScore W3168111521C104317684 @default.
• W3168111521 hasConceptScore W3168111521C126322002 @default.
• W3168111521 hasConceptScore W3168111521C134018914 @default.
• W3168111521 hasConceptScore W3168111521C141035611 @default.
• W3168111521 hasConceptScore W3168111521C142724271 @default.
• W3168111521 hasConceptScore W3168111521C150903083 @default.
• W3168111521 hasConceptScore W3168111521C185592680 @default.
• W3168111521 hasConceptScore W3168111521C207001950 @default.
• W3168111521 hasConceptScore W3168111521C2775842073 @default.
• W3168111521 hasConceptScore W3168111521C2776359302 @default.
• W3168111521 hasConceptScore W3168111521C2776925932 @default.
• W3168111521 hasConceptScore W3168111521C2779134260 @default.
• W3168111521 hasConceptScore W3168111521C2989005 @default.
• W3168111521 hasConceptScore W3168111521C3017724952 @default.
• W3168111521 hasConceptScore W3168111521C42219234 @default.
• W3168111521 hasConceptScore W3168111521C55493867 @default.
• W3168111521 hasConceptScore W3168111521C71924100 @default.
• W3168111521 hasConceptScore W3168111521C86803240 @default.
• W3168111521 hasLocation W31681115211 @default.
• W3168111521 hasOpenAccess W3168111521 @default.
• W3168111521 hasPrimaryLocation W31681115211 @default.
• W3168111521 hasRelatedWork W1930895061 @default.
• W3168111521 hasRelatedWork W2028823687 @default.
• W3168111521 hasRelatedWork W2035778678 @default.
• W3168111521 hasRelatedWork W2093375978 @default.
• W3168111521 hasRelatedWork W2362412603 @default.
• W3168111521 hasRelatedWork W2466758786 @default.
• W3168111521 hasRelatedWork W2521585476 @default.
• W3168111521 hasRelatedWork W2806931468 @default.
• W3168111521 hasRelatedWork W2910377713 @default.
• W3168111521 hasRelatedWork W2922037411 @default.
• W3168111521 hasRelatedWork W3031458933 @default.
• W3168111521 hasRelatedWork W3032240267 @default.
• W3168111521 hasRelatedWork W3080216490 @default.
• W3168111521 hasRelatedWork W3085744412 @default.
• W3168111521 hasRelatedWork W3136775325 @default.
• W3168111521 hasRelatedWork W3158206732 @default.
• W3168111521 hasRelatedWork W3165064593 @default.
• W3168111521 hasRelatedWork W3166675572 @default.
• W3168111521 hasRelatedWork W3172503575 @default.
• W3168111521 hasRelatedWork W3200567638 @default.
• W3168111521 hasVolume "62" @default.
• W3168111521 isParatext "false" @default.
• W3168111521 isRetracted "false" @default.
• W3168111521 magId "3168111521" @default.
• W3168111521 workType "article" @default.